The Committee for Medicinal Products for Human Use (at European Medicines Agency) has not yet given its regulatory opinion for brigatinib and as a consequence the discussion at the technology appraisal committee meeting on 12 July 2018 will take place in a Part 2 session (Part 2 sessions are closed to public observers).